Cypress Capital Group Buys 3,850 Shares of Solventum Corporation $SOLV

Cypress Capital Group grew its stake in shares of Solventum Corporation (NYSE:SOLV) by 20.7% during the second quarter, HoldingsChannel reports. The firm owned 22,425 shares of the company’s stock after purchasing an additional 3,850 shares during the quarter. Cypress Capital Group’s holdings in Solventum were worth $1,701,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the stock. Independent Franchise Partners LLP boosted its stake in shares of Solventum by 263.1% during the 1st quarter. Independent Franchise Partners LLP now owns 5,820,724 shares of the company’s stock valued at $442,608,000 after purchasing an additional 4,217,570 shares in the last quarter. Davis Selected Advisers boosted its stake in shares of Solventum by 0.8% during the 1st quarter. Davis Selected Advisers now owns 5,288,138 shares of the company’s stock valued at $402,110,000 after purchasing an additional 41,524 shares in the last quarter. Boston Partners boosted its stake in shares of Solventum by 101.3% during the 1st quarter. Boston Partners now owns 3,361,973 shares of the company’s stock valued at $255,554,000 after purchasing an additional 1,691,565 shares in the last quarter. Northern Trust Corp boosted its stake in shares of Solventum by 3.3% during the 1st quarter. Northern Trust Corp now owns 1,807,674 shares of the company’s stock valued at $137,456,000 after purchasing an additional 58,373 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Solventum by 2.2% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 1,173,960 shares of the company’s stock valued at $89,268,000 after purchasing an additional 24,762 shares in the last quarter.

Solventum Stock Down 1.8%

Shares of Solventum stock opened at $70.53 on Monday. The company has a debt-to-equity ratio of 2.14, a quick ratio of 0.86 and a current ratio of 1.22. The stock has a market capitalization of $12.23 billion, a PE ratio of 32.65, a price-to-earnings-growth ratio of 2.87 and a beta of 0.50. Solventum Corporation has a 52-week low of $60.70 and a 52-week high of $85.92. The company has a 50-day simple moving average of $72.75 and a two-hundred day simple moving average of $72.08.

Solventum (NYSE:SOLV) last issued its earnings results on Thursday, August 7th. The company reported $1.69 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.24. The business had revenue of $2.16 billion during the quarter, compared to analysts’ expectations of $2.12 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the previous year, the company earned $1.56 earnings per share. Solventum has set its FY 2025 guidance at 5.800-5.950 EPS. On average, analysts anticipate that Solventum Corporation will post 6.58 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. UBS Group assumed coverage on shares of Solventum in a research report on Wednesday, October 1st. They set a “neutral” rating and a $77.00 price target for the company. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and lifted their price target for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Wells Fargo & Company lifted their price target on shares of Solventum from $79.00 to $82.00 and gave the company an “equal weight” rating in a research report on Monday, September 15th. Finally, Piper Sandler reissued an “overweight” rating and set a $94.00 price target (up from $87.00) on shares of Solventum in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.